Eminent physicians to offer treatment, consultations in Abu Dhabi in May
SAMIHAH ZAMAN (ABU DHABI)The Department of Health – Abu Dhabi (DoH), the emirate's health regulator, has announced a list of eminent physicians who are scheduled to offer treatment and consultations in Abu Dhabi this month (May).The doctors will head to Abu Dhabi as part of the DoH Visiting Physicians Programme, providing care and support in wide range of medical specialties – including oncology, paediatric haematology and orthopaedic surgery – across Abu Dhabi's healthcare facilities.'The DoH welcomes top-tier doctors from around the world to the Emirate during May, offering exceptional healthcare services through the Visiting Physicians Programme,' the DoH announced.
Visiting Physicians Among the doctors headed to Abu Dhabi as part of the programme is Dr. Denise Adams, Paediatric Haematologist-Oncologist, and Director of the Comprehensive Vascular Anomalies Programme at the Children's Hospital of Philadelphia. An expert in rare tumours and vascular treatment, Dr. Adams will be available at the Sheikh Khalifa Medical City between May 19 and 21.Another cancer expert, Dr. Leslie Lehmann, International Medical Director for Haematology/Oncology/Bone Marrow Transplant at the Dana Farber and Boston Children's Hospital, ranked the top children's hospital in the US, will see patients at the Yas Clinic Khalifa City between May 20 and 23.In the field of orthopaedic medicine, Dr. Austin T. Fragomen, Consultant Orthopaedics and Limb Lengthening Surgeon at HSS Hospital New York, the top ranked orthopaedic hospital in the US, will offer services at the Healthpoint Hospital between May 19 and 23. Dr. Fragomen specialises in skeletal reconstruction, deformity correction, bone lengthening surgery, fracture care, and minimally invasive limb surgeries.From the Paley Institute – another of the top orthopaedic care centres in the US – Dr. Dror Paley, Medical Director of the Division of Critical Care at the St. Mary Hospital, Paley Institute, and Prof. Munjed Al Muderis, Consultant Orthopaedic Surgeon at St. Mary Hospital, Paley Institute, West Palm Beach, will head down to Burjeel Medical City in Abu Dhabi. The two physicians specialise in advanced orthopaedic care and surgery, including limb lengthening, amputation care, limb reconstruction, deformity correction, and bone cancer treatment. Dr. Paley will be available between May 25 to 30, whereas Prof. Al Muderis will visit between May 21 to 26.Ocularist Paul Geelen, provider of eye implants and prosthetic eyes at the Artificial Eye Services Hospital in Perth, Australia, will see patients at Abu Dhabi's Moorfield Eye Hospital between May 11 and 25.Patients can directly contact the respective hospitals to book appointments, the DoH has urged.
Programme MilestonesAs of December 2024, a total of 3,277 patients with rare and complex medical conditions have received care in Abu Dhabi from 37 visiting experts as part of the Visiting Physician Programme. Launched by the DoH in 2021, the programme aims to provide exceptional healthcare services by partnering with leading global health organisations. It has seen the completion of 372 successful surgeries in the emirate, including the first dorsal rhizotomy surgery, which is used in the treatment of children with cerebral palsy. According to the DoH, the top five specialties offered by visiting practitioners in 2024 include paediatric haematology for bone marrow transplants; plastic surgery for lymphedema and brachial plexus, adult orthopaedic surgeries for complex ankle, foot, shoulder, hand and scoliosis, paediatric orthopaedic care for limb lengthening and limb deformities, and ophthalmology.Of the 1,985 patients who sought treatment through the programme in 2024, 94% were successfully treated and did not need to travel abroad for treatment, the DoH has revealed.
In addition to the provision of consultative services, the programme has allowed for knowledge transfer, the enhancement of local expertise and post-surgical rehabilitation care, and the improvement of healthcare outcomes throughout Abu Dhabi.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
7 hours ago
- Al Etihad
Abu Dhabi leads high-level delegation to US, showcasing emirate's global leadership in healthcare innovation
8 July 2025 13:10 ABU DHABI (ALETIHAD)Department of Health – Abu Dhabi (DoH) has led a high-level delegation on a strategic mission to the US to strengthen partnerships and showcase Abu Dhabi's excellence in life sciences and precision visit reflected the emirate's global leadership in healthcare innovation and its commitment to international cooperation to advance scientific research, innovation, and ethical medical delegation visited key US cities including Boston, Washington DC, and Philadelphia, in parallel with Abu Dhabi's participation at BIO International Convention 2025, one of the world's foremost biotechnology visit spotlighted the emirate's achievements in AI, digital health, genomics, and clinical research, and showcased Abu Dhabi's Health, Endurance, Longevity and Medicine (HELM) Life Science Cluster, while promoting long-term strategic partnerships with government entities, research institutions, and global Excellency Dr Noura Khamis Al Ghaithi, Undersecretary of DoH, said: 'This mission demonstrated Abu Dhabi's ongoing efforts to cement its position as a global centre of excellence in health and life sciences. We are committed to fostering partnerships that advance healthcare innovation and enhance quality of life, both in the UAE and globally.'The delegation conducted more than 20 strategic meetings and visits with public and private sector leaders across the US, aimed at enhancing knowledge exchange and investment opportunities, and marked the signing of new agreements that will accelerate the adoption of advanced health mission facilitated joint actions between DoH and global organisations set to shape the future of healthcare. These alliances reinforce the Emirate's steadfast dedication to advancing health outcomes through impactful global collaborations, pioneering research and a robust infrastructure that fosters innovation, talent and investment. Key agreements and partnerships were formed with prestigious US-based peers and partners, including the University of California, San Francisco, the Innovative Genomics Institute, Sanofi, Boehringer Ingelheim, Abbott, Aetna International, GEMMABio and Children's National Hospital. These collaborations focus on establishing genome surgery centres, advancing vaccine development and manufacturing, integrating innovative research platforms and localising pharmaceutical production, while also expanding access to US healthcare networks, developing genomics and biotechnology research centres and launching advanced cell and gene therapy programmes for the side-lines of Abu Dhabi's participation at BIO International Convention in Boston, USA, the Department of Health – Abu Dhabi, in collaboration with Johnson & Johnson (J&J) and Sheikh Shakhbout Medical City (SSMC), a flagship hospital in the UAE for serious and complex care and a subsidiary of the PureHealth group, have successfully enabled expedited access to Tremfya®, a next-generation biologic medication for patients with Inflammatory Bowel Disease (IBD). This strategic partnership marks the first availability of the treatment outside the United States, reinforcing Abu Dhabi's position as a as a pioneering destination for healthcare innovation and advanced, patient-focused Abu Dhabi's innovation ecosystem, the delegation included key stakeholders such as Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD Group, PureHealth, StartAD, Khalifa University, New York University Abu Dhabi, and Etihad Dhabi continues to lead the region in genomics through the Emirati Genome Programme, which has successfully sequenced more than 800,000 samples, creating one of the most advanced national genomic databases. The emirate is also home to more than 90 licensed research centres and over 30 ongoing clinical trials in areas such as oncology, rare diseases, and chronic data platforms such as Malaffi, which securely store over 5 million patient records—enable AI-powered insights and real-world evidence, while national initiatives like the Golden Visa have enabled more than 2,000 long-term visas for researchers and healthcare professionals from around the world. This strategic visit reflected Abu Dhabi's broader vision for healthcare transformation—driven by innovation, investment, and a deep commitment to global collaboration.
Al Etihad
2 days ago
- Al Etihad
Abu Dhabi to welcome top-tier physicians from US, South Korea, Australia this July
7 July 2025 00:59 SAMIHAH ZAMAN (ABU DHABI)Abu Dhabi will once again welcome several leading physicians in a bid to offer expert healthcare and medical services within the to Abu Dhabi as part of the Department of Health- Abu Dhabi (DoH) Visiting Physicians Programme , the doctors will provide medical care and advice in plastic surgery, paediatric oncology, ophthalmology, and spine care.'The DoH welcomes top-tier doctors from around the world to the Emirate during July, offering exceptional healthcare services through the Visiting Physicians Programme,' the DoH announced on its social media Michael Grimley, paediatric haematologist-oncologist at Cincinnati Children's Hospital, US, is one of the quartet of doctors heading to the UAE capital this month. Dr. Grimley specialises in the care of anaemia, sickle cell disease, haemophilia, leukaemia, and lymphoma. He will see patients at the Sheikh Khalifa Medical City between July 7-11, Geelen, ocularist at the Artificial Eye Services Hospital in Perth, Australia, will see patients at Moorfields Eye Hospital between July 13 -17, 2025. Geelen has more than two decades of experience in the making and fitting of hand crafted artificial Zeeshan Sardar, associate chief of spine and scoliosis surgery at the New York Presbyterian Hospital, US, will meanwhile be available at Healthpoint Hospital between July 28 and August 1, 2025. Dr. Sardar is an expert in the treatment of adult scoliosis, ankylosing spondylitis, complex spine surgery, and degenerative spine Joon Pio Hong, consultant plastic surgeon at Asan Medical Center, South Korea, has also offered medical care for lymphoedema, lipoedema, and diabetic foot at Abu Dhabi's Tarmeem Hospital and Healthpoint Hospital this DoH has urged patients and their families to book appointments with the experts by contacting the respective health care in 2021 with the aim of providing top-notch healthcare within Abu Dhabi, the Visiting Physicians Programme has enabled more than 300 surgeries, and seen the contribution of more than 30 visiting experts from around the world. As of December 2024, more than 3,200 patients had received treatment and consultation in Abu Dhabi as part of the initiative. Source: Aletihad - Abu Dhabi
Al Etihad
3 days ago
- Al Etihad
Abu Dhabi to partner with GEMMABio Therapeutics, advance gene therapies for children with spinal muscular atrophy
5 July 2025 19:52 ABU DHABI (WAM)The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has announced its plans to partner with GEMMABio Therapeutics (GEMMABio), a pioneering global biotechnology company dedicated to advancing global access to gene therapies for rare diseases, in collaboration with M42, a global health champion powered by AI, technology and genomics, and PureHealth, the largest healthcare group in the Middle East. The announcement follows a high-level meeting, during the BIO International Convention 2025 in Boston, between senior leaders from GEMMABio and key stakeholders from Abu Dhabi's health and life sciences ecosystem. Through this strategic partnership, the entities will jointly establish dedicated manufacturing and research centres within Abu Dhabi's academic health institutions, enabling patients from across the MENA region to access cutting-edge clinical trials and, eventually, approved gene collaboration will kick off with a clinical trial evaluating a next-generation gene therapy product in children with spinal muscular atrophy type 1 (SMA1), setting a precedent for expanding access to life-saving therapies Mohamed Alameri, Acting Director of Genome and Biobank Division at the Department of Health – Abu Dhabi, said, 'Our partnership with GEMMABio marks a pivotal step in Abu Dhabi's journey to become a global leader in developing gene therapies for rare diseases leveraging the Emirati Genome Programme. At DoH, we are committed to reshaping innovation, early detection and personalised care by strengthening the Emirate's capacity to develop, test and scale innovative therapeutics. Through these efforts, we are advancing life sciences applications while offering real hope to patients and families across the region and beyond.'The collaboration will unite the shared vision and technology to further strengthen Abu Dhabi's gene therapy R&D ecosystem, and see the emirate serving as a regional hub for GEMMABio's translational and clinical research activities.A best-in-class gene therapy contract development and research manufacturing organisation will be established in Abu Dhabi as a joint venture between M42 and GEMMABio. Additionally, regional access to GEMMABio's commercialised gene products will be coordinated through Abu Dhabi's gene therapy research and treatment by the emirate's state-of-the-art infrastructure, forward-looking policies and the Health, Endurance, Longevity and Medicine (HELM) Life Sciences Cluster, Abu Dhabi is offering streamlined licensing and co-commercialisation processes, alongside co-investment schemes and tax relief for biotech startups. Together, these enablers position Abu Dhabi as a leading global hub for life sciences Jim Wilson, Founder, President, and CEO of GEMMABio, said, 'This is a transformational partnership—one that will play a pivotal role in unlocking global access to life-saving treatments for patients with rare diseases. The stakeholders in Abu Dhabi are building a globally recognised gene therapy ecosystem whose impact on the future of life sciences will be both profound and far-reaching. Together, we are aligning scientific innovation with bold ambition to accelerate progress where it's needed most.'Dimitris Moulavasilis, Group Chief Executive Officer of M42, said, 'This partnership helps Abu Dhabi usher in another frontier in the future of health. With our integrated AI- and data-led ecosystem and advancements in precision, prevention, and prediction, this collaboration extends the impact of the Emirati Genome Programme into gene therapeutics targeting rare diseases."M42 is focused on developing genomic insights, fighting against rare diseases and saving lives. Our partnership with the Department of Health – Abu Dhabi and GEMMABio will accelerate this effort, ensuring people in the UAE and beyond get the gene therapies they need for longer, healthier lives.'This strategic partnership reinforces Abu Dhabi's recent strides in rare disease gene therapies and precision medicine. The emirate has significantly expanded its genomics capabilities through the Emirati Genome Programme, with over 800,000 genome samples sequenced, marking one of the world's most advanced national genomic Dhabi continues to pioneer the administration of cutting-edge gene therapies, expanding access to life-saving treatments that were previously unavailable in the region. With sustained investment in research, talent, and infrastructure, the emirate is reinforcing its position as a regional leader in life sciences and medical Saif Al Qubaisi, Group Chief Operating Officer of PureHealth, said, 'This collaboration is a powerful reflection of Abu Dhabi's growing influence as a global centre for health innovation. By joining forces with GEMMABio and our strategic partners, we are not only expanding access to advanced gene therapies, but also reinforcing the Emirate's long-term commitment to solving some of the world's most complex health challenges. PureHealth is proud to contribute through its integrated research capabilities and commitment to clinical excellence, aligned with the Department of Health's vision to deliver life-changing outcomes for patients across the region and beyond.'Led by DoH, a high-level delegation embarked on a strategic mission to the US from June 15 to 21, 2025. This visit focused on knowledge exchange, investment opportunities, and the signing of new agreements aimed at accelerating the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation included key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Cargo, New York University Abu Dhabi (NYUAD), Khalifa University, and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI), and startAD.
